Vivo Capital Portfolio 2026

12 companies backed by Vivo Capital, including Ajax Therapeutics, EpiBiologics, Sanegene Bio. Each links to its full verified cap-table syndicate.

Vivo Capital accounts for 54 tracked companies with verified cap-table data, 54 of which disclose round sizes totalling $7.9B. The median disclosed raise is $127M, and the largest is Gracell Biotechnologies at $520M, ahead of Tebra ($387M) and Avistone Pharmaceuticals ($340M).

The names that recur most often on these portfolio cap tables are Vivo Capital (54 companies), Logos Capital (11 companies), Cormorant Asset Management (10 companies), OrbiMed (9 companies), RA Capital Management (9 companies), Lilly Asia Ventures (7 companies). By latest disclosed round, the market skews Series B (15), Series A (9), Series C (8), IPO (5).

Best funded Vivo Capital companies

  1. Gracell Biotechnologies — $520M (latest: IPO)
  2. Tebra — $387M (latest: Growth)
  3. Avistone Pharmaceuticals — $340M (latest: Series A)
  4. Aadi Bioscience — $265M (latest: IPO)
  5. Impel NeuroPharma — $250M (latest: IPO)
  6. Aligos Therapeutics — $225M (latest: Series B)
  7. Coherus Biosciences — $220M (latest: Series C)
  8. SonoThera — $215M (latest: Series B)
  9. dMed — $214M (latest: Series B)
  10. Ronovo Surgical — $211M (latest: Series D)
  11. Attralus — $201M (latest: Series B)
  12. ADARx Pharmaceuticals — $200M (latest: Series C)
  13. Serán BioScience — $200M (latest: Growth)
  14. Terns Pharmaceuticals — $197M (latest: IPO)
  15. Kinnate Biopharma — $195M (latest: Series C)

Vivo Capital — related firms and companies (56)

Vivo Capital profile · All research reports